BTIG Research Begins Coverage on Tempus AI (NASDAQ:TEM)

Equities researchers at BTIG Research assumed coverage on shares of Tempus AI (NASDAQ:TEM - Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The firm set a "buy" rating and a $60.00 price target on the stock. BTIG Research's price objective indicates a potential upside of 21.09% from the stock's previous close.

Several other research firms have also issued reports on TEM. Loop Capital cut their target price on Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a research note on Tuesday, January 14th. TD Cowen restated a "buy" rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Guggenheim reaffirmed a "buy" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Needham & Company LLC restated a "buy" rating and set a $70.00 target price on shares of Tempus AI in a research note on Thursday, April 10th. Finally, William Blair reissued a "market perform" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $61.08.

Tempus AI Trading Up 14.6 %

Shares of NASDAQ:TEM traded up $6.32 during trading hours on Monday, hitting $49.55. The company's stock had a trading volume of 18,684,270 shares, compared to its average volume of 5,611,071. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The firm's fifty day moving average price is $51.22 and its 200 day moving average price is $50.38. Tempus AI has a 52 week low of $22.89 and a 52 week high of $91.45.

Insiders Place Their Bets

In other Tempus AI news, Director Wayne A.I. Frederick sold 3,000 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $45.54, for a total transaction of $136,620.00. Following the completion of the sale, the director now directly owns 26,514 shares in the company, valued at approximately $1,207,447.56. The trade was a 10.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 85,788 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $53.39, for a total value of $4,580,221.32. Following the completion of the transaction, the chief executive officer now owns 5,771,787 shares in the company, valued at approximately $308,155,707.93. This trade represents a 1.46 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,670,040 shares of company stock worth $277,450,802.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently modified their holdings of the business. Operose Advisors LLC purchased a new position in shares of Tempus AI during the fourth quarter worth $25,000. Cherry Tree Wealth Management LLC purchased a new stake in Tempus AI during the first quarter worth about $31,000. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth about $34,000. Prestige Wealth Management Group LLC boosted its stake in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after purchasing an additional 965 shares during the period. Finally, Continuum Advisory LLC acquired a new position in shares of Tempus AI in the first quarter valued at approximately $39,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.